Aurinia Pharmaceuticals is a biopharmaceutical company that develops and sells treatments for diseases with unmet medical needs in the US and worldwide. Their primary product is LUPKYNIS, a drug that treats active lupus nephritis in adult patients. They have a collaboration and license agreement with Otsuka Pharmaceutical Co. and their headquarters is in Victoria, Canada.